Lazard Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-435
| Closed | -$45K | – | 2429 |
|
|
2025
Q1 | $45K | Sell |
435
-224
| -34% | -$23.2K | ﹤0.01% | 2014 |
|
|
2024
Q4 | $70K | Sell |
659
-1,507
| -70% | -$160K | ﹤0.01% | 1909 |
|
|
2024
Q3 | $216K | Hold |
2,166
| – | – | ﹤0.01% | 1592 |
|
|
2024
Q2 | $181K | Buy |
2,166
+981
| +83% | +$82K | ﹤0.01% | 1591 |
|
|
2024
Q1 | $86K | Hold |
1,185
| – | – | ﹤0.01% | 1587 |
|
|
2023
Q4 | $84K | Hold |
1,185
| – | – | ﹤0.01% | 1728 |
|
|
2023
Q3 | $71K | Buy |
1,185
+641
| +118% | +$38.4K | ﹤0.01% | 1752 |
|
|
2023
Q2 | $39K | Buy |
+544
| New | +$39K | ﹤0.01% | 1908 |
|
|
2023
Q1 | – | Sell |
-7,269
| Closed | -$485K | – | 2444 |
|
|
2022
Q4 | $485K | Hold |
7,269
| – | – | ﹤0.01% | 1131 |
|
|
2022
Q3 | $625K | Buy |
7,269
+6,383
| +720% | +$549K | ﹤0.01% | 1064 |
|
|
2022
Q2 | $79K | Hold |
886
| – | – | ﹤0.01% | 1604 |
|
|
2022
Q1 | $99K | Buy |
886
+19
| +2% | +$2.12K | ﹤0.01% | 1405 |
|
|
2021
Q4 | $133K | Buy |
867
+65
| +8% | +$9.97K | ﹤0.01% | 1362 |
|
|
2021
Q3 | $111K | Sell |
802
-72
| -8% | -$9.97K | ﹤0.01% | 1391 |
|
|
2021
Q2 | $114K | Buy |
874
+10
| +1% | +$1.3K | ﹤0.01% | 1311 |
|
|
2021
Q1 | $131K | Hold |
864
| – | – | ﹤0.01% | 1163 |
|
|
2020
Q4 | $85K | Buy |
+864
| New | +$85K | ﹤0.01% | 1222 |
|
|
2019
Q4 | – | Sell |
-5,449
| Closed | -$542K | – | 1602 |
|
|
2019
Q3 | $542K | Buy |
5,449
+3,187
| +141% | +$317K | ﹤0.01% | 814 |
|
|
2019
Q2 | $258K | Sell |
2,262
-1,314
| -37% | -$150K | ﹤0.01% | 1000 |
|
|
2019
Q1 | $449K | Buy |
3,576
+2,535
| +244% | +$318K | ﹤0.01% | 932 |
|
|
2018
Q4 | $141K | Buy |
+1,041
| New | +$141K | ﹤0.01% | 889 |
|
|
2014
Q4 | – | Sell |
-18,455
| Closed | -$867K | – | 1152 |
|
|
2014
Q3 | $867K | Buy |
+18,455
| New | +$867K | ﹤0.01% | 696 |
|